글로벌 진단용 전기생리학 카테터 시장 – 2023-2030

Overview
Global Diagnostic Electrophysiology Catheters Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.9 billion by 2030, growing with a CAGR of 8.1% during the forecast period 2023-2030.
Diagnostic Electrophysiology Catheters in the field of cardiology are specialized medical devices that are crucial in identifying and understanding various cardiac arrhythmias and other electrophysiological abnormalities. These catheters are used to assess and diagnose abnormal electrical activity in the heart. They are introduced into the heart through blood vessels and provide real-time data and mapping of the heart's electrical signals.
Diagnostic electrophysiology catheters are designed and configured for specific applications. They have multiple electrodes capable of recording electrical signals from different regions of the heart. This helps cardiologists and electrophysiologists to pinpoint the source of arrhythmias and evaluate the overall heart function.
Moreover, diagnostic electrophysiology catheters are often used in conjunction with advanced imaging technologies, such as fluoroscopy and 3D mapping systems, to enhance visualization and improve the precision of catheter placement. Furthermore, the rising prevalence of cardiac arrhythmias, increasing adoption of electrophysiology mapping systems, and innovations in diagnostic electrophysiology catheters are the factors expected to drive the market over the forecast period.
Dynamics
The Increasing Product Launches by the Key Market Players is Expected to Drive the Market Growth
On October 13, 2022, the HELIOSTAR Balloon Ablation Catheter was released by Biosense Webster, a subsidiary of Johnson & Johnson MedTech, and is the first radiofrequency balloon ablation catheter available in the European market. It is specifically designed for catheter-based cardiac electrophysiological mapping of the atria and cardiac ablation when used alongside a compatible multi-channel RF generator. Its unique feature is the presence of ten gold-plated, irrigated electrodes, which can be customized to deliver power based on anatomical location and tissue thickness. The HELIOSTAR catheter is capable of both circumferential and segmental ablation, which allows for personalized pulmonary vein (PV) ablation. Additionally, the ability to control power delivery to each electrode independently enhances its flexibility and efficacy.
Similarly, on July 24, 2023, the OPTRELL Mapping Catheter with TRUEref Technology was introduced to the cardiac arrhythmia treatment market in the U.S. by Biosense Webster, Inc., a significant player under Johnson & Johnson MedTech. This diagnostic catheter, developed alongside the CARTO 3 System, features a fixed array configuration with a high-density arrangement of small electrodes. This configuration is ideal for precise electrophysiological mapping in complex cardiac arrhythmia cases, including persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
The recent release of the HELIOSTAR and OPTRELL catheters by Biosense Webster highlights the importance of innovative technologies in addressing challenges in cardiac electrophysiology. These advanced tools cater to the increasing need for precise, efficient, and customizable approaches to cardiac mapping and ablation. Biosense Webster's dedication to enhancing patient outcomes, simplifying procedures, and improving the overall landscape of arrhythmia treatment is evident in these new product launches.
Innovations in Diagnostic Electrophysiology Catheters are Expected to Drive Market Growth
On May 4, 2022, Siemens Healthineers introduced the AcuNav Volume 4D ICE Catheter, which is a significant advancement in intracardiac echocardiography (ICE) technology in the United States. The catheter's distal tip is innovative, improving maneuverability and visualization of critical structures. This development enables physicians to get closer to the anatomy and provide better care during structural heart procedures.
The latest advancement is especially beneficial for patients who were previously unable to undergo such procedures due to contraindications like transesophageal echo (TEE) or general anesthesia, as well as those with tricuspid regurgitation. The catheter's design also aims to enhance hospital efficiency, reduce cath lab turnaround time, and eliminate the need for general anesthesia. Siemens Healthineers' position as a leader in diagnostic imaging technology is further strengthened by the AcuNav Volume ICE Catheter's precision and improved outcomes in structural heart procedures.
Therefore, the diagnostic electrophysiology catheters market could experience further growth due to the availability of advanced catheters like the AcuNav Volume ICE Catheter, which would benefit patients, healthcare providers, and the industry as a whole. Hence, owing to the above factors, the market is expected to drive the market over the forecast period.
High Cost for Diagnostic Electrophysiology Catheters Adoption is Expected to Hamper the Market Growth
The high expenses associated with diagnostic electrophysiology catheters and their required equipment can hinder their adoption. One such catheter, the Electrophysiology Catheter BIOSENSE WEBSTER: D7TCJ8L162RT, has a size of 7 Fr, an insertion length of 115 cm, a J-curve type, 4 electrodes, an 8 mm tip electrode, and a spacing of 1-6-2 mm, making it a promising medical tool for diagnostic interventions. However, despite its potential, the market's growth may face significant obstacles during the projected forecast period. The cost of $600.97 per unit may create a significant economic barrier for healthcare facilities with limited budgets.
Segment Analysis
The global diagnostic electrophysiology catheter market is segmented based on type, technology, end user and region.
The RF Ablation Catheters from the Type Segment Accounted for Approximately 38.9% of the Diagnostic Electrophysiology Catheters Market Share
Radiofrequency (RF) Ablation Catheters are advanced medical devices used in different procedures to treat conditions such as cardiac arrhythmias and specific tumors. These catheters use controlled radiofrequency energy to destroy abnormal tissue without requiring open surgery. They offer advantages such as enhanced accuracy in targeting specific tissue, decreased patient discomfort, shorter recovery periods, and reduced risks compared to traditional surgical methods.
For instance, Medtronic, The 7 French RF Marinr Multi-Curve Steerable Catheter is a specialized medical tool used in minimally invasive interventional cardiology procedures. It has a diameter of 7 French and is designed to navigate the cardiovascular system with ease, thanks to its multiple pre-shaped curves that enhance maneuverability.
This catheter is primarily intended for radiofrequency ablation, which is used to treat cardiac arrhythmias by delivering controlled energy to selectively destroy irregular heart tissue. The catheter's steerable capabilities enable precise navigation through complex pathways, which improves control for accessing challenging anatomical sites and performing delicate procedures effectively.
When combined with RF ablation, this catheter enhances patient outcomes, reduces procedure times, and increases comfort compared to traditional surgical methods. To ensure optimal use and patient care, healthcare professionals must receive proper training in using this catheter.
Furthermore, the RF Ablation catheter market is driven by factors such as the increasing prevalence of cardiac arrhythmias, rising demand for minimally invasive treatment options, and advancements in catheter technology.
For instance, on March 15, 2023, received CE (Conformité Européenne) Mark for the Affera Mapping and Ablation System, which includes the Sphere-9 Catheter and the Affera Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and provides real-time feedback through its intuitive mapping and navigation software.
Moreover, Atrial fibrillation (AFib) is the most common atrial arrhythmia, and nearly 60 million people are affected worldwide and five million patients will be added every year by 2030. Atrial arrhythmias, such as AFib, are associated with serious complications including heart failure, stroke, and increased risk of death.
Additionally, on May 15, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that data from the Q-FFICIENCY study was published in JACC: Clinical Electrophysiology. The study evaluated the safety and 12-month effectiveness of the QDOT MICRO Catheter in paroxysmal atrial fibrillation (AFib) ablation using the very high-power short-duration (QMODE+) mode combined with conventional-power temperature-controlled (QMODE) mode.
The Biosense Webster QDOT MICRO Catheter is a next-generation RF ablation catheter that was granted CE Mark in 2020 and FDA approval in 2022. This catheter is designed to provide improved procedural efficiency and ablation efficiency for treating atrial fibrillation (AF). It is the world's first very high-power, short-duration ablation catheter.
Nevertheless, the market growth can be impeded by challenges like limited awareness among patients and healthcare professionals, high upfront costs of equipment, and the requirement for specialized training to operate the devices effectively. Therefore, these obstacles require continuous medical education, cost-effective solutions, and ongoing research to demonstrate the safety and efficacy of RF ablation procedures.
Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing FDA Approvals, Growing Product Launches, and Presence of Key Market Players in the Region
North America region is expected to hold the largest market share over the forecast period owing to the increasing FDA approvals, growing product launches, and presence of key market players in the region. For instance, on February 2, 2023, Abbott announced two approvals as part of its growing suite of electrophysiology products in the global market. The company’s TactiFlex Ablation Catheter, Sensor Enabled, the world’s only ablation catheter with a flexible tip and contact force sensing, received CE Mark for treating people with abnormal heart rhythms like atrial fibrillation (AFib). Abbott’s FlexAbility Ablation Catheter, Sensor Enabled also recently secured an expanded indication for treating patients with a complex heart condition by the U.S. Food and Drug Administration (FDA).
Similarly, on February 2, 2023, MicroPort EP obtained approval from the Food and Drug Administration in the United States of America (U.S.) for its independently researched and developed EasyFinder Fixed Curve Diagnostic Catheter. This product is the first mapping catheter from MicroPort EP to get FDA approval.
Therefore, the approval of more diagnostic electrophysiology catheters by the FDA in the region has a significant positive impact on the market. It encourages innovation, improves patient care, increases clinical confidence, attracts investments, and establishes the region as a leader in the field. Moreover, there is potential to revolutionize the diagnosis and treatment of heart rhythm disorders, leading to benefits for both healthcare providers and patients. Thus, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.
Competitive Landscape
The major global players in the diagnostic electrophysiology catheters market include Abbott Laboratories, Boston Scientific Corporation, Johnson and Johnson (Biosense Webster), Integer Holdings Corporation, Medtronic, Lepu Medical Technology (Beijing)Co., Ltd., Access Point Technologies EP., BIOTRONIK, CathRx Ltd. and Siemens Healthineers among others.
COVID-19 Impact Analysis
COVID-19 has significantly impacted the diagnostic electrophysiology catheters market. Due to the pandemic's peak, hospitals had to delay or cancel elective procedures, including diagnostic electrophysiology procedures. As a result, the usage of diagnostic electrophysiology catheters decreased, and healthcare resources were redirected toward managing COVID-19 cases.
Patients with non-urgent cardiac conditions often postpone routine check-ups and diagnostic tests due to their fear of exposure to the virus. This decrease in patient visits resulted in less demand for diagnostic electrophysiology catheters. The focus of hospitals and medical facilities shifted to managing COVID-19 cases, which meant that essential and life-threatening procedures took priority. Elective diagnostic procedures like electrophysiology studies using catheters were deprioritized during this time. The pandemic also had an impact on research and development activities, with potential delays to the introduction of new and innovative diagnostic electrophysiology catheter technologies to the market.
With the improving situation of the pandemic and the stabilization of healthcare systems, the market for Diagnostic Electrophysiology Catheters is anticipated to slowly bounce back. The demand for precise diagnosis and treatment of heart conditions is still present, and the market is expected to recover as elective surgeries resume, patients regain trust, and healthcare resources are redirected toward non-COVID-19-related services.
By Type
• RF Ablation Catheters
• Alternative Energy Ablation Catheters
o Cryoablation
o Laser Ablation
o Ultrasound
• High-Density Mapping Catheters
• ICE Catheters
By Technology
• Fixed Curve Diagnostics Catheters
• Steerable Diagnostics Catheters
By End User
• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On July 24, 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced the U.S. launch of the OPTRELL Mapping Catheter with TRUEref Technology powered by the CARTO 3 System. The OPTRELL Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia.
• On September 06, 2022, Royal Philips, a global leader in health technology, announced that Baptist Health’s Miami Cardiac & Vascular Institute (Florida, U.S.) successfully started treating patients with Verisight Pro, Philips’ real-time 3D Intracardiac Echocardiography (ICE) catheter, during minimally-invasive image-guided procedures for structural heart disease. Offering superior 2D and 3D live imaging, VeriSight Pro allows interventionalists to navigate procedures with ease, provide superior care, and optimize the performance of the interventional suite to benefit more heart patients.
DataM Intelligence Opinion:
According to DataM Intelligence, the diagnostic electrophysiology catheter market is being driven by new and innovative products, such as the HELIOSTAR Balloon Ablation Catheter and AcuNav Volume 4D ICE Catheter. These advancements demonstrate the industry's dedication to improving cardiac electrophysiology tools.
However, the COVID-19 pandemic has created challenges for the market, including delays in procedures and fewer patient visits. Despite these setbacks, the market is expected to recover due to the importance of accurate diagnosis, ongoing advancements, and North America's strong presence in the industry, thanks to FDA approvals. Collaboration between medical professionals, researchers, and manufacturers will be crucial in shaping the future of the market, improving patient care, and making the industry more adaptable. This will lead to sustained growth and a positive global impact.
Why Purchase the Report?
• To visualize the global diagnostic electrophysiology catheters market segmentation based on type, technology, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diagnostic electrophysiology catheters market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global diagnostic electrophysiology catheters market report would provide approximately 61 tables, 58 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies